microdose glp 1 GLP-1 Microdosing Chart: Tirzepatide and Semaglutide Microdosing GLP-1: Should You Try

Survodutide was found to significantly lower HbA1c in comparison with a placebo in a phase II trial where it was administered subcutaneously once and twice a week [103]

J., Jacobsson H., et al

Evidence of GLP-1 agonist cardiovascular benefit acroos all subgroups independent of glycemic control

In that regard, actual market dominance appears to be significantly driven by simplicity of use, dosing schedule, injection site discomfort, robust efficacy, indication and contraindication in certain subpopulations, and low side-effect profile along with non-scientific factors, such as first-to-market, size and experience of the companys diabetes sales force, negotiated pricing and reimbursement agreement, geographic areas of regulatory approvals and patent exclusivity

The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial was a pivotal milestone as it showed the cardiovascular benefits of liraglutide in patients with T2D and high cardiovascular risk